Health Care • Biotechnology: Pharmaceutical Preparations
$26.83 ▼ -0.45
(-1.65%)
MKT CAP: $3.48B • VOL: 4.43M
52W L $24 52W H $43
VKTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.10B | $422.6M | $282.3M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$393.3M | -$150.9M | -$100.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$359.6M | -$110.0M | -$85.9M |
| EBITDA (Normalized) | -$393.3M | -$150.9M | -$100.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$278.7M | -$87.8M | -$73.4M |
| Capital Expenditures (CapEx) | $0 | $0 | $0 |
| Free Cash Flow (FCF) | -$278.7M | -$87.8M | -$73.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -13.8% | -7.1% |
| Cash & Short-Term Equivalents | $165.8M | $26.7M | — |
| Total Debt (Short + Long Term) | $34.5M | $12.6M | $434.5M |
| Total Stockholders' Equity | $639.1M | $880.3M | $891.3M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VKTX.